WhiteLab Genomics Raises $26 Mn Series B to Advance AI-Designed Genomic Medicines

The funding round was led by AVP, with participation from new investors Yaday Health and Blast Club. Existing investors Omnes Capital and Debiopharm Innovation Fund also joined the round.

WhiteLab Genomics will use the new funding to speed up its in vivo testing programmes across viral and non-viral delivery technologies and programmable genetic payloads. The company will also use the funding to expand its business across North America, Europe, and Asia.

The company aims to build a portfolio of experimentally tested biological assets that it can develop on its own or together with biopharmaceutical partners.

“AI can help us design better genomic medicines, but what ultimately matters is whether those designs work in living systems,” said David Del Bourgo, co-founder and CEO of WhiteLab Genomics. “We have already presented compelling results. This financing allows us to scale that work across multiple delivery technologies and payloads, build a portfolio of validated bio-assets and bring them to biopharma partners around the world.”

“WhiteLab is building AI that designs genomic medicines that actually work in vivo, not just on paper,” said François Robinet, managing partner of AVP. “AI is about to have a real, tangible impact on genomic medicine and to contribute meaningfully to the development of new therapies.The combination of computational design, experimental validation and the ability to translate those designs into differentiated bio-assets is what attracted us to the company. We are very excited to join the journey and support David and the team as they enter this next phase.”

“WhiteLab is at an inflection point," said Dr. Daniel Teper, Managing Partner of Yaday Health. "Their scientific approach is validated in vivo. The development of AI-designed bio-assets and expansion in the United States are what carry that from a platform capability to assets that drug developers can advance.”

Founded in 2019, WhiteLab Genomics works with major industrial and academic organisations, including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris, and the Paris Brain Institute. The company also has partnerships with other biotechnology companies.

WhiteLab Genomics is part of Y Combinator, Station F, and Future4Care, and has also been named a French Tech 2030 laureate.

Read Also-